text:
Development of PK/PD Model for Individualized Propofol Dosing
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The U.S. National Health and Nutrition Examination Survey of 1994 indicated that 59% of American men and 49% of women have body mass indexes (BMIs) over 25. Extreme obesity, defined as a BMI of 40 or more, was found in 2% of the men and 4% of the women [http://www.cdc.gov/nchs/nhanes.htm]. The newest survey in 2007 indicates an alarming increase in BMI; 63% of Americans are overweight, with 26% now in the obese category. With extreme obesity as high as 26-30% in adults, obesity percentages in children are also sharply on the rise. These alarming numbers pose a major clinical problem in terms of the safe and effective use of drugs in children.
Obesity may alter the disposition and/or clearance of drugs in the body as well as the response, which should be considered when using anesthetics in these patients. Total intravenous anesthesia (TIVA) with propofol is widely used in children, adolescents and adults undergoing surgery, because of rapid onset of action, ease of titration and rapid offset of action. While extensive research on optimal propofol dosing has been performed in non-obese adults, including in critically ill mechanically ventilated adult patients by the investigators' collaborators, there is no evidence on required dosages in morbidly obese adult or pediatric patients of this highly lipophilic agent. As a consequence, serious problems do arise due to under- and overdosing, increasing the risk of inadequate effects and adverse events, respectively. Crucial additional information is needed on the pharmacokinetics of drugs used in morbidly obese children to improve safety and efficacy.
This proposal will test a novel approach by identifying pharmacokinetic/pharmacodynamic (PK/PD) factors that are associated with response to therapy and adverse events. If successful, this study will provide proof of concept data for PK/PD model-based dosing strategy that can be implemented into daily clinical care to allow tailoring of dose to individual needs. Propofol is a versatile anesthetic agent which if dosed to individual needs based on a patient's characteristics and specific PK/PD parameters, will allow individualized dosing, thereby greatly reducing related toxicities. The prospective identification of predictive factors in these morbidly obese high-risk patients represents a new approach to an increasingly common clinical problem. The investigators expect that this study will generate the PK/PD data necessary to continue with a well powered prospective clinical trial.
|Obesity Elective Surgery
|Study Type:
|Study Design:
|Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:
|A Non-Interventional Study to Develop a Pharmacokinetic - Pharmacodynamic Model for Individualized Propofol Dosing
- Change in propofol clearance and volume of distribution (for determination of effective concentration); Depth of anesthesia. [ Time Frame: Samples will be analyzed within one month of collection ]
- Population PK/PD model (NON-MEM) using patient demographic and clinical data. [ Time Frame: one year ]
Biospecimen Retention: Samples With DNA
|Study Start Date:
|July 2009
|Study Completion Date:
|December 2013
|Primary Completion Date:
|July 2012 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
|5 Years to 18 Years (Child, Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
|Sampling Method:
|Non-Probability Sample
Inclusion Criteria:
- Age 5 to 18 years of age;
- Have a Body Mass Index (BMI) greater than 30;
- Be scheduled for bariatric or other elective surgical procedure;
- Will be administered propofol anesthesia as part of procedure and standard of care and subject is expected to be under anesthesia for at least 60 minutes;
- Signed and dated IRB-approved Informed Consent or Parental Permission and Assent form, as applicable.
Exclusion Criteria:
- Patients receiving investigational agent as part of another clinical study;
- Patients with severe developmental delay, known neurological disorders;
- Conditions where the placement of the sensor or process of assessment could interfere with the BIS monitoring;
- Allergy to propofol / anaphylaxis to egg protein;
- History of severe sleep apnea;
- Anticipated difficult airway access;
- Significant allergies and sensitivities to tape and/or adhesives.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00948597
|United States, Ohio
|Cincinnati Children's Hospital Medical Center
|Cincinnati, Ohio, United States, 45229
|Principal Investigator:
|Alexander A Vinks, PharmD, PhD
|Children's Hospital Medical Center, Cincinnati
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:
|Children's Hospital Medical Center, Cincinnati
|ClinicalTrials.gov Identifier:
|NCT00948597 History of Changes
|Other Study ID Numbers:
|Study First Received:
|July 27, 2009
|Last Updated:
|January 8, 2014
Keywords provided by Children's Hospital Medical Center, Cincinnati:
elective surgical procedure
Obese subjects
Additional relevant MeSH terms:
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anesthetics, Intravenous
Anesthetics, General
ClinicalTrials.gov processed this record on September 21, 2017


text:
Verona, NY — A 48-year-old Central New York man faces drunken driving charges after state police found him sleeping at the wheel of his damaged vehicle in a convenience store parking lot.
Troopers say officers on patrol spotted a Honda Odyssey idling in a parking lot in Verona at 3 a.m. Saturday with front end damage and a flat tire. The driver, Joseph Gleeson of Delhi, woke up when they approached.
Troopers say Gleeson told them he believed he had struck a snowbank while driving from the nearby Turning Stone Casino. Police say a breath test showed Gleeson's blood alcohol content to be .20 percent, more than twice the legal limit.
He was sent to the Oneida County Jail for lack of $1,500 bail to await a court appearance on driving while intoxicated charges.

subset: commoncrawl


text:
Please enter your username and password here:Forgot Password?
Please enter your details here:or Login
By ExpatBriefing.com Editorial
22 April, 2014
Singapore-based Oversea-Chinese Banking Corporation Ltd (OCBC Bank) has announced that it will expand its business in Greater China by fully acquiring Hong Kong-listed Wing Hang Bank Ltd (WHB).
OCBC Bank said in a statement that the acquisition will allow it to capitalize on Greater China's strong economic growth and the increased connectivity between north and southeast Asia. The bank noted that the deal is consistent with its goal of deepening its presence in Singapore, Malaysia, Indonesia, and the Greater China region (China, Hong Kong, Macau, and Taiwan).
Through the acquisition, OCBC will add WHB's 70 branches in Hong Kong, Macau, and Mainland China to its existing network of 19 branches and sub-branches in Mainland China, Hong Kong, and Taiwan.
The acquisition will provide OCBC Bank with a sizable platform from which to grow its RMB-denominated businesses, the bank said. The range of RMB products and services could be developed or enhanced further to include treasury, trade finance, cash management and payments, capital markets and offshore wealth management offerings.
Currently, in addition to serving corporates and retail customers, WHB has built a Small- and Medium-Enterprise (SME) customer franchise in China and carved a niche for itself in auto and equipment financing in Hong Kong and Macau. OCBC Bank said the deal would open up opportunities for cross-selling wealth and bancassurance products and services to WHB's affluent retail customers and SME entrepreneurs.
Tags: Business | Banking | Capital Markets | Entrepreneurs | China | Macau | Singapore | Taiwan | Offshore | Hong Kong | Indonesia | Malaysia | Retail | Trade | Services | Expats | Banking
About | Useful Links | Global Media Partners | Media | Advertising And Sales | Banners And Widgets | Glossary | RSS | Privacy & Cookies | Terms And Conditions | Editorial Policy | Refer To A Friend | Newsletters | Contact | Site Map
Important Notice: Wolters Kluwer TAA Limited has taken reasonable care in sourcing and presenting the information contained on this site, but accepts no responsibility for any financial or other loss or damage that may result from its use. In particular, users of the site are advised to take appropriate professional advice before committing themselves to involvement in offshore jurisdictions, offshore trusts or offshore investments. © Wolters Kluwer TAA Ltd 2017. All rights reserved.
The Expat Briefing brand is owned and operated by Wolters Kluwer TAA Limited.


text:
ELYRIA — Elyria Catholic may struggle on the ice this year with only eight skaters and it showed in Wednesday night's 6-2 loss to Lakewood in the Greater Cleveland High School Hockey League opener for both clubs in the White West Division.
The Panthers (0-2, 0-1) went up early, but then had no answer for the Rangers Zach Moran, who scored four times and added an assist in the win for Lakewood (1-1, 1-0).
"We are skating with seven or eight kids and they are getting gassed out there," Panthers coach Rick Montgomery said. "I thought our defense played solid for the most part and we have new players out there that are learning the game and it's going to be a work in progress for us this year."
Elyria Catholic struck first with 9:11 left in the opening period when sophomore David Kukucka picked up a loose puck on the wing and fired on goal to beat Lakewood's Hunter Nugent.
Kukucka wasn't done in the period though, firing a wrist shot about 30 seconds later to break the glass behind the Lakewood goal that resulted in a 21-minute delay.
The score looked like it would hold up through the first period until Moran picked up the puck near the end line and beat the Panthers' Luke Farmer through the five-hole to knot the game at one with 16 seconds left in the period.
"One of the new guys out there learned that you can't turn the puck over right there, because it cost us," Montgomery said. "You can play well for an entire period and one mistake can cost you."
The importance of the late goal was not lost on Moran.
"Getting a goal late like that in the period can really propel you," Moran said. "I just wanted to keep the offensive pressure up at the end of the period and I got lucky getting the puck in the five-hole from such a tough angle by the end line.
"When you score like that, you want to come out in the next period and keep up the pressure. We were able to get that done."
Moran scored just 22 seconds into the second period when he one-timed the puck on a pass from teammate Nate Bonacuse from behind the EC goal for a 2-1 lead.
The two Rangers traded spots on the next score when Moran assisted on Bonacuse's score with 11:44 on the second period clock for a 3-1 advantage.
Despite being outshot 19-6 in the second period, the Panthers had a pair of late chances but were turned away both times by Nugent, who finished the night stopping 14 of 16 Elyria Catholic shots on goal.
Kukucka had a shorthanded breakaway chance with 6:38 on the clock and Will Gentry took a long pass at center ice and skated in only to be stonewalled by Nugent.
"Those saves at the end of the night are as important as us putting the puck in the net," Rangers coach Josh Dress said. "(EC) moved the puck up quickly and they snuck behind our defenders. He was able to make a couple of really big saves."
Moran put the game away for Lakewood, scoring twice in the first four minutes of the third period on assists by Luke Walkush and Tommy Kettel for his first career four-goal game.
The Panthers did pick up a late score from Gentry, who gathered in a loose puck off a Ranger stick for an unassisted goal.
Contact James Brady at 329-7135 or email@example.com. Follow James on Twitter @jbrady_ct.
Lakewood 6, Elyria Catholic 2
FIRST PERIOD: (EC) David Kukucka (unassisted), 9:11, (L) Zach Moran (Donny McRae). SECOND PERIOD: (L) Moran (Nate Bonacuse), 14:38, (L) Bonacuse (Moran), 11:44. Penalties: (EC) Paul Demer (tripping), 6:38. THIRD PERIOD: (L) Moran (Luke Walkush), 13:42, (L) Moran (Tommy Kettel), 11:22 PP, (EC) Will Gentry (unassisted), 5:40, (L) Joe Young (Walkush, Matt Johnson). Penalties: (EC) Kukucka (holding), 12:19.
Lakewood 1 2 3 — 6
Elyria Catholic 1 0 1 — 2
Shots on goal: Elyria Catholic 16 (6-6-4), Lakewood 50 (15-19-16). Goalies: Elyria Catholic: Luke Farmer (50 shots, 44 saves); Lakewood: Hunter Nugent (16 shots, 14 saves). Power-play opportunities: Elyria Catholic 0-0, Lakewood 2-1.


text:
$ 209.00
La LOOP Sunset Garnet Spinel Necklace 265P plated Silver Loop. La LOOP is the premier accessory in the eyewear industry. Have you every been fed up with misplacing your eyeglasses, sunglasses-at home, in the office, on the go Than you need La LOOP. A creative solution to an everyday problem with products of high quality and sophisticated styling. La LOOP necklaces integrate the highest quality materials with international fashion trends.
A faceted sunset garnet spinel necklace approximately 25 inches long with plated silver 23mm thin hinged Loop and clasp that is attach to a necklace. Slide a temple of any eyewear into the loop and the loop rotates on patented swivel hinges enabling gravitational force to keep your eyewear securely in place. Garnet cleanses and re-energises the chakras. It revitalises, purifies and balances energy, bringing serenity or passion as appropriate. Inspires love and devotion. Garnet balances the sex drive and alleviates emotional disharmony. It activates and strengthens the survival instinct, bringing courage and hope. Stimulates past-life recall. Sharpens perceptions of oneself and others. Garnet removes inhibitions and taboos. It opens the heart and bestows self-confidence.. This necklace adds just the right chic and modern touch to any look.
Included with this necklace is a La LOOP pouch.
La LOOP is for the overextended and style-conscious professionals, parents, students, homemakers Š—" The perfect gift - a modern accessories that both served a function and looked great on.


text:
Read the full story here Web Link posted Wednesday, November 16, 2011, 7:02 PM
Town Square
Caltrans plans to spray chemicals along Hwy. 84
Original post made on Nov 17, 2011
Read the full story here Web Link posted Wednesday, November 16, 2011, 7:02 PM
a resident of Atherton: other
on Nov 17, 2011 at 12:41 pm
I would like to know more about the moratorium. Last Summer a SM county truck was spraying Round Up at 3am in the sidewalk cracks and roadside. They had lights, a noisy generator (which woke me up)and a man with a long hose attached to a following truck. This was confirmed when I asked them what they were spraying in the middle of the night. The residents were given NO notification, which is par for the course but ALWAYS surprises Supervisor Jacobs-Gibson.
a resident of Menlo Park: Downtown
on Nov 17, 2011 at 8:22 pm
Why not just cut the weeds. I'm one of those who likes to pick and eat blackberries that grow along the roadsides, but I had to stop after being informed about possible spraying.


text:
NEW YORK (TheStreet) -- Alcoa (AA) jumped early in Tuesday's session after receiving an upgrade from JPMorgan. The investment firm upgraded the stock to "overweight" from "neutral" and raised its price target to $15 to reflect tightening aluminum markets and rising regional aluminum premiums on earnings.
"Given the pace and amount at which premiums have recently increased, it is clearly difficult to forecast for how long they will remain near current levels which we believe provide a significant amount of earnings support to the company's primary aluminum smelting operations," wrote JPMorgan analyst Michael F. Gambardella in the report.
The firm increased its 2014 earnings estimates to 78 cents a share from 40 cents a share and fiscal 2015 earnings to 68 cents a share from 55 cents a share. Analysts surveyed by Thomson Reuters anticipate net income of 32 cents a share in fiscal 2014 and 58 cents a share in fiscal 2015.
The world's third-largest aluminum producer enjoyed a strong surge in share prices last week, after announcing it would close two potlines at its Massena East plant in New York state on the grounds they were not competitive anymore. The company also said it plans to expand its Davenport, Iowa factory, a plant dedicated to supplying aluminum to car and truck producers.
On Friday, the Pittsburgh-based business announced its board had approved a quarterly dividend of 3 cents a share payable Feb. 25 to common stock shareholders of record at the close of Feb. 7. On its cumulative preferred stock priced at $3.75 a share, the company will offer a quarterly dividend of 93.75 cents a share on April 1 to shareholders of record at the close of March 14.


text:
New School Opens in Former Kmart
As they first approached the brand-new G. Weaver Hipps Elementary School this fall, some residents of Lehigh Acres, Fla., may have remembered going back-to-school shopping in that very location just a few years earlier. Newcomers to the area, however, would not have known that the building that houses the new school used to be a Kmart.
In 2003, administrators in Lee County Public Schools had to decide what to do about the district's rapidly growing population. From July 2000 to July 2003, the county had added almost 50,000 residents.
Although they were using about a thousand portable units across the district and could have added more, they chose instead to purchase an abandoned Kmart and transform it into a "staging school," a temporary facility that would house students for one to two years while a new building was constructed for them.
Reggie Snell, the district's director of construction services, says it was an easy decision. "All of the infrastructure was already there—water, sewer, sprinkler systems. It was a lot cheaper to do that than to build massive 'portable farms.'" The district purchased the building and land for $4 million, a decision welcomed by area residents. "They were happy to see an empty building become a school," says Snell.
Snell says that the building was wide open when renovations began, so workers were able to get right to work. They built lots of walls, installed a bathroom for every classroom, replaced the rooftop air conditioning units, and created 10-foot-high drop ceilings. Electrical lines and ductwork were installed easily in the eight to nine feet of space above the ceilings.
Outside, workers converted sections of the building's large parking lot to fields and play spaces. "The people in the water management district liked that," says Snell.
After serving as a staging school for a high school and two elementary schools, the building is now the permanent home of G. Weaver Hipps Elementary, the fifth elementary school in Lehigh Acres and the 47th in the district.
Principal Scott LeMaster says that additional work was done to prepare for housing the new school, such as adding small walls and safety doors at the entrance to the three hallways that branch out from the reception area, a much-needed security enhancement.
"In 16 years of working in education, this is by far the nicest facility I've been in, and I've been in some pretty nice facilities," says LeMaster.


text:
This adjusting screw connects the top of the injector with the rocker arm.
From the self study guide: "After installing a pump/injector, the minimum clearance between the base of the high-pressure chamber and the pump piston must be adjusted at the pump/injector adjusting screw. This adjustment prevents the pump piston from knocking against the base of the high- pressure chamber due to heat expansion."


text:
CafeMom Veteran
Click on a link to search for moms with the same information
Click on a link to search for other moms with the same favorites
by EmilyMiller posted at 10:25 PM on Nov. 2
, 2007
by EmilyMiller posted at 2:50 PM on Oct. 21
, 2007
by EmilyMiller posted at 12:26 PM on Oct. 18
, 2007
by EmilyMiller posted at 2:50 AM on Oct. 14
, 2007
by EmilyMiller posted at 6:29 PM on Oct. 2
, 2007
enter textenter texttexttextI am Amy I am the group owner to the group True Friends For Life. The chat room is open daily from 7am-3pm central time hope to see you in chat room soon.
Hey...haven't heard from you in awhile and was just checking in to see how everything is going?
Hi there! I am the owner of Tulsa Mommies and I noticed you haven't been active lately. I wanted to invite you to come and join in on the conversation!
Sorry I was going to drop a note on Romans birthday but I was at work and didnt get on the computer at home that day! Hope that he had a wonderful 1st bday! Happy belated Birthday little man!
Congrats on the Tat! What is it of? I still havent gotten around to getting my wrist one I want!
Featured Posts in All Groups


text:
Jekyll Island is six miles off the Georgia coast, midway between Savannah, GA, and Jacksonville, FL, and just minutes off Interstate 95. When you arrive, you'll find the hustle and stress of everyday life seem to drift away through the moss-draped live oaks and swaying pines. Forget traffic, crowds, neon signs and high-rise buildings. On Jekyll Island, you'll find a safe environment with an inviting combination of resort amenities in an unspoiled barrier island setting.
Golf Zoo offers the best golf courses available as well as your choice in accommodations. Create a custom online trip quote 24/7 by selecting your dates and number of adults on the trip quote box on the right side of this page. Creating your own custom golf package to Jekyll Island has never been easier. Please use our Interactive Area Map to assist in choosing your golf courses and accommodations, it's really easy to use and gives you lot's of information - including directions, overhead satellite views, complete listing of golf and lodging properties, images & descriptions!


text:
Mejorar el SEO de mi página
Budget €30-250 EUR
Hola, tengo una tienda online que vende marcas de lencería sexy y erótica y me gustaría mejorar el posicionamiento natural para atraer más tráfico de calidad y de España a la web.
¿Tienes alta experiencia en SEO? ¿Me quieres ayudar con el proyecto?
Estoy encantada de escuchar tu propuesta.
67 freelancere byder i gennemsnit €116 for dette job
Get Organic Traffic from Search Engines to Your Website using White hat SEO practices. Experienced SEO team, White Hat On-Page and Off-Page SEO, No Hidden Fees, No Setup Fees, and No Long Term Contracts. Look No Furt Mere
HI, We have 10+ years SEO experience can do white hat SEO for references please check our reviews 2900+ reviews with Good Rehire Rate we can do white hat SEO as per Google guideline Please give your website URL f Mere
Hello from Europe, If you see our Review and rating then you know we are ranked #1 on SEO: [url removed, login to view] I am here for long term and my SEO strategy works as per Google's recent u Mere
Hi, I'm a ☛ TOP RANK SEO FREELANCER - SEO LEVEL 3 QUALIFIED ☛ PREFERRED FREELANCER BADGE HOLDER ☛ 98% Job Completion Rate ☛ with more than 8 YEARS of PROFESSIONAL EXPERIENCE. KINDLY MESSAGE ME TO DISCUSS FURTHER TH Mere
Hi Sir, We are having 11+ Years SEO experience and TOP RANK SEO FREELANCER . Our SEO technique is always based on the latest search engine algorithms (From the Recent Penguin/Panda hummingbird etc. Updates). We pro Mere
Hello, We are one of the leading SEO Internet Marketing Company in India. We can rank your website on first page and can improve your website's organic traffic by doing white hat SEO. As all know SEO is an ongoing p Mere
Hi Sir, We fully aware about Google Panda, Google Penguin, and Google Hummingbird, Panda 4.0. and 4.1 . I will prepare complete strategy . How? I rank my clients using safe techniques with organic back linking, Mere
Hi, I am offering Top Quality SEO Service including (On Page + Off Page Optimization). I am here to increase your website traffic by implementing my extraordinary On-Page issues fixing techniques. Currently work Mere
"SEO LEVEL 3 - EXAM PASSED" Dear Sir, How Can I Rank in Google Top pages? 1. With White Hat Methods 2. Strong 300+ Monthly Back links Report 3. Advance and Complete On Site Optimization Mere
Hello sir, i read the project details, willing to work and rank site at google.. i will Guarantee the Result and ranking within 2- 3 MONTH at top on google page 1 === we have done 400 projects and have 5 year Mere
hello sir, we are SEO level 3 have done 600+ projects can rank any website by our SEO plan and methods please discuss with us further for more details about us thanks!!
Hello, We will achieve your website on Google 1st page top 10 positions within 3 to 4 months. We will do only white hat On-page and Off-page SEO using all Google Guidelines or Panda safe . We are best web developer, Mere
HI, We are an experienced and talented team of Professional SEO consultants. We are passionate about helping you to build and expand your business by doing ethical work. Our skilled SEO team is well-versed in taking Mere
Hello, I am Anand an expert in SEO and SMO. I have more than 5 Years of experience in On-page and Off-page SEO. I always use white hat SEO techniques and follow Google guidelines to jump up your website at Google to Mere


text:
Trying out xfce 4.6.1 in current some questions
I am a kde user, and I am trying to go xfce, however I have some questions.
1. Is there a nicer graphical login, without installing kdm?
2. Is there a way to mount other partitions easily?
3. Can you get the desktop icons to activate with single click?
4. Can you allow users to shutdown/restart?
5. Can you attach a terminal to thunar rather than open a terminal here?
I can answer a few of your questions:
1) XFCE does not have a log in manager, you need to use GDM or KDM
4) http://wiki.xfce.org/faq#session_manager
1)I knew it had, look at /etc/inittab, there's written:
# 4 = X11 with KDM/GDM/XDM (session managers)
# If all you have is XDM, I guess it will have to do:
2)My partitions are always mounted automatically by the kernel at the startup, just add some line to /etc/fstab, or mount em launching by terminal:
# mount -a
3)I don't know, never used xfce...
4)It doesn't depend by the desktop environment, it depends by the powers that an user has got, your user shouldn't probably got them, and you shouldn't add these powers to him, we're talking about a security issue, if you add these powers to your user might happen that running a normal bad script that is written for rebooting your machine...You know, it's not a good, it shouldn't happen, you're running linux where users gotta have their own powers, remember, your user ain't root and won't be root.
5)I don't know :)
#4: For XFCE, you allow users (or a group) to execute /usr/libexec/xfsm-shutdown-helper as root.
(use visudo to edit /etc/sudoers)
Sorry, didn't notice that info was already linked from post #2 ;)
question 4
add the users to the power group
Many thanks for the replies. It seems that while xfce 4.6.1 is now much better than it ever has been, it is still not quite where I want it to be.
1. I installed KDM, however as it is embedded in a base KDE package I just ended up installing KDE anyway. It seems that important parts of xfce4.6.1 are either missing or not bundled with Slackware.
2. See point one. It appears you can download an add-on, but I would have thought that this was a fundamental part of file management.
3. You can activate a single click for files, but not desktop items. Surely everything in unix/linux/bsd is a file.
4. After reading the documentation and making sure that power was the user specified by haldaemon, and adding the user to that group, it just didn't work. Guess this could be a problem in the Slackware implementation.
5. Cannot be done, so I guess you will just have to have loads of terminals created, or use dolphin.
I also found a few other irritations, to me, so I have reverted to KDE, and once you strip out all the fancy effects and additional programs, it looks a bit like xfce.
Did you try the "sudo" method for #4?
No I didn't, I prefer to use groups wherever possible, or su when necessary. However xfce power manangement has just been updated in current and that might fix the problem for me.
It is a shame that XFCE is not complete out of the box as it has potential, but whilst I am capable of making the required changes I am lazy, and I feel that basic stuff like the ability to turn off the computer or look at your hard drives should be included in the base package.
So I'm back to KDE, at least I have plenty of resources that it can hog.
|All times are GMT -5. The time now is 12:50 PM.


text:
WILMINGTON, Mass. — The Boston Bruins held an informal practice Thursday — their third of the week at Ristuccia Arena — to help them get back into shape and rekindle chemistry before the start of rookie camp Sept. 11 and training camp Sept. 18.
The skate also is open to other NHL players who live in the Boston area. One player who showed up Thursday was Phoenix Coyotes defenseman Keith Yandle, who was born in Milton. He has been at all three of the B's informal practices this week and has skated with Boston at summer sessions in previous years.
Toward the end of practice, Yandle did a shooting drill with a few other Bruins.
New Jersey Devils goaltender Cory Schneider arrived for the first time Thursday, sporting red Devils pads and mask. Schneider was born in Marblehead and played three seasons at Boston College from 2004-05 through 2006-07. He got some playing time against the Bruins during the 2011 Stanley Cup Final when Vancouver Canucks starter Roberto Luongo was pulled from Games 4 and 6 at TD Garden.
Veteran defenseman Ryan Whitney, who played seven games for the Florida Panthers last season, also participated. He's a Scituate native who played three seasons at Boston University.
The Bruins will have another informal practice Friday at Ristuccia.
— Milan Lucic was wearing a visor, which could be a permanent change for him this season. The veteran winger skated for a little while before the practice officially began.
Looch on the ice ^CS #NHLBruins http://t.co/YrKhnmF9B4—
Boston Bruins (@NHLBruins) September 04, 2014
— Patrice Bergeron, Loui Eriksson, Daniel Paille and Zdeno Chara were among the Bruins veterans absent from Thursday's practice. Chris Kelly was the only captain present.
— David Pastrnak displayed his excellent puck-handling skills in drills. He was asked about playing alongside fellow Czech Republic forward David Krejci and replied, "(Krejci) signed for six years, so I have seven years to make the team."
— Former Bruins defenseman Hal Gill was in charge of Thursday's skate. He played in six games for the Philadelphia Flyers last season.
Powered by WordPress.com VIP


text:
This property has been removed by the agent. It may be sold or temporarily removed from the market
2 bedroom semi-detached house for saleSt. Marys Road
Property Description
Key features
- Victorian Home
- Semi-detached
- 2 Double Bedrooms
- Open Plan Living
- Character Features
- Family Bathroom
- Modern fitted Kitchen
- Popular Location
- 0.5 Mile from Train Station
- 0.5 Mile to Tonbridge Grammar School
Full description
Tenure: Freehold
If you're a first time buyer looking to get onto the property ladder or simply just looking for a bit more space, then this gorgeous Victorian home situated only 0.5 miles from Tonbridge train station could be what you are after.
Energy Performance Certificate (EPC) graphs
Listing History
Map & Street View
View in fullscreenView in fullscreen
Street View is unavailable in this location
Market Info
Disclaimer - Property reference TBR150231. The information displayed about this property comprises a property advertisement. Rightmove.co.uk makes no warranty as to the accuracy or completeness of the advertisement or any linked or associated information, and Rightmove has no control over the content. This property advertisement does not constitute property particulars. The information is provided and maintained by Howard Cundey, Tonbridge. Please contact the selling agent or developer directly to obtain any information which may be available under the terms of The Energy Performance of Buildings (Certificates and Inspections) (England and Wales) Regulations 2007 or the Home Report if in relation to a residential property in Scotland.
Map data ©OpenStreetMap contributors.


text:
September 19, 2011 to October 1, 2011 – The Kittredge Center, Holyoke Community College Energy Conservation Training Company Intensive Course: Mon-Fri & Mon-Sat - 8am-5pm Tuition Fee Includes: Classroom instruction Hands-on field training at local private residences Books and st… Organized by Jeff Catlin | Type: training, &, bpi, certification
September 29, 2011 at 8am to October 2, 2011 at 5pm – DoubleTree Dallas Campbell Centre CleanEdison's Building Performance Institute (BPI) Building Analyst for HERS Raters course is the same as the BPI Building Analyst course, only at a discounted price. By sending us the certificate sh… Organized by Cmot Cho | Type: training, class
© 2017 Created by Lawrence Berkeley National Laboratory. Powered by


text:
Site Sections
About This Site
Section Links
related pages
this page last modified
MRI Scans
A Diagnostic Procedure
I used the following in the following discussion; the first four are excellent references which you might be interested in reading for yourself.
- A Machine Called Indomitable, by Sonny Kleinfield (1985). This book is an excellent read, written by a journalist, "the remarkable story of a scientist's inspiration, invention, and medical breakthrough."
- Nuclear Medicine, a volume of the Encyclopedia of Health (1994), by Wendy and Jack Murphy.
- Medicine's New Vision by Howard Sochurek (1988). This book has excellent photographs, descriptions, and stories of people whose disease was diagnosed by modern imaging techniques.
- Everything You Need to Know About Medical Tests, edited by Breanndan Moore (1996).
- Various Organic Chemistry texts, as well as the Handbook for Organic Chemistry Lab (CU Boulder), written by yours truly.
The Technical Facts
Magnetic Resonance Imaging, "MRI", is a relatively new imaging technique. The first images were scanned in the 1970s, and in the 1980s its use became widespread. It really should be called "NMRI", as it is based on a technique employed by scientists to study the structure of molecules, a technique called NMR for Nuclear Magnetic Resonance. But, the public associates "nuclear" with nuclear bombs, radioactive substances, and other such nasties, therefore, they dropped the word nuclear to make it more palatable to the layman.
In the context of NMR, nuclear stands for the nucleus of the atom. Recall, the nucleus is the positively charged "center" of an atom. Some atoms have nuclei which "spin" on an axis, examples are hydrogen, carbon, nitrogen, fluorene, and phosphorus.
Why is this "spin" important to MRI? Consider hydrogen, with a nucleus of one proton. This nucleus spins around like a top. Since it has a positive charge, as it spins it generates a magnetic dipole along the spin axis, as shown in the figure to the right. In a normal, non-treated sampling of hydrogen atoms, the magnetic dipoles will orientate in random directions. However, if a magnetic field is applied, they will line up with the magnetic field:
I have shown the spinning nucleis' magnetic dipoles in two colors on purpose, because half of the dipoles will be of a higher energy "red" and half will be of a lower energy "blue". Once they are lined up by a magnet, they are zapped with energy in the form of low energy electromagnetic radiation (radiowaves), which causes the blue protons to become as energetic as the red protons:
The lower energy "blue" protons are able to accept one and only one size package (or quantum: quantum chemistry!) of energy -- energy in the form of light, or radiation -- and if that package is given to it, it jumps to a higher energy level, and becomes just like a red.
But, there is only room in the higher energy level for half of the high energy dipoles, so half of them must soon give up their energy and drop back down. When they drop back down, they each give off a tiny amount of energy:
The technicians know exactly what frequency of radiation to look for, because the nuclei are only giving up specific size packages of energy. It is the energy given off by the protons which signals the detector and leads to the MRI image given to the doctor.
What happens to the other atoms in the body, all the ones that are not hydrogen? Well, each nuclei that is able to (i.e., has a magnetic dipole) will line up with the field. But, the package of energy which each of these nuclei can accept is different than the package size the hydrogens take, so, they will not jump to a higher energy level when zapped with the radiowaves, and hence will not give off radiation.
So, you might ask, why would detecting hydrogens in the body help the diagnostician? Most of the signals in an MRI scan originate from the hydrogens of water molecules, because these hydrogens are far more abundant in tissues than are the hydrogens of organic compounds. The difference in the way water is bound in different tissues is what produces much of the signal variation among the organs as well as the signal variation between healthy and diseased tissue. With practice and experience, people -- technicians -- learn to decipher the scans and tell diseased tissue from healthy tissue.
What It's Like To Have an MRI
To have an MRI, the whole person must fit into a huge magnet and then lie very still for 45 minutes to 2 hours. You are able to speak through an intercom to the technician. Some people become quite claustrophobic. The instrument produces no harmful rays so the technician or family members can remain close by. During the scan, the magnet will effect anything metal, so you must not wear any jewelry or anything made of metal. Some people say that their fillings tingle during the scan. The magnetic is a superconducting magnet, cooled with liquid helium. As each separate image is scanned, the pulsing magnet bangs and thumps. Sometimes a contrast is injected to produce better pictures.
Advantages MRI Over X-Ray Scans
The electromagnetic radiation used to charge the hydrogen atoms is much, much lower in energy and much less damaging than X-rays. The magnet itself has not been shown to have any adverse effect on humans, even though it produces a magnetic field 10,000-30,000 times greater than that of the earth! There is no limit to the number of MRI scans a person can have.
MRI can see right through bones and other hard tissues. It gives images of brain tumors, abscesses, swelling, bleeding, nerve damage, and other disorders that increase the fluid content of tissues.
The instruments cost well over $2 million. They require about $10,000 per month for upkeep, like the liquid helium. Plus, they generally take longer to acquire than do X-ray type scans. These costs are of course passed on to the patient -- depending on the length of the scan, the MRIs cost $2,000 - $4,000 in MRI time alone, not accounting for the time of the various technicians and doctors also involved.
The Parent Facts
An adult may require mild sedation to overcome the claustrophobic effects of an MRI, but what about a child? This will depend on many things, like age, personality, and the current state of the child's disease.
- "Because Eric needed general anesth. for scans, we would always try to get a couple of procedures done at the same time, so Eric was under the general for the duration of the scan and usually an LP or BM or whatever else. He would go to the anesthesia suite (known here as PACU), be put under, be transported up to MRI and then returned to PACU for whatever the other treatment was and then recovery. The anesthesiologist stayed with him the whole time."
- "The first few times Mary had a great deal of trouble staying still. She was frightened of the noise (it sounds like a loud moterboat or jackhammer) and she didn't like it. They wanted to sedate her but she promised to keep still (anything to avoid another needle). After a while (the last couple of years) she learned to calmly ask for the earplugs and go to sleep. They used to talk to her on a loudspeaker to tell her when the next set would begin, but she finally told them to knock it off, she was asleep.
- MRI's are such a time consuming effort, I always tried to schedule several things (CT, bone scan, hearing tests) in the same day. You have to plan to take the entire day off and just be with your child. They never seemed to go off without a hitch. If we were on time for an appt. (or early) we would have to wait. If we were running late, we would get scolded for messing up their "schedule" (like they ever stuck to it). Nothing metallic could be worn into the room with the MRI. Once I had a barrette in my hair with a metal clasp and when I got close to the machine, the magnet lifted the barrette off my scalp towards the machine. Mary couldn't wear overalls with buckles, shoes with eyelets, jewelry, her Mickey Mouse watch or her hat with the barrette attached. Everything was stored in a locked cubby outside the room. She would usually be given pillows, blankets, and a foam knee-rest to make lying there as comfortable as possible. She hated changing into a hospital gown, so we made sure that plain T-shirts and stretch pants were what she wore. Most technicians were pretty good about allowing her to wear her own clothes.
- She would stick earplugs in her ears, and after a while, the drone of the machine taking its pictures would put her to sleep. Most of the time her arms would be at her side, but once she put them behind her head. The images that we saw later on film with her arms up looked pretty funny. We also had to be careful that her central line was away from her body and not in the pictures."
- "When Jake has his MRI's he doesn't have to much problems as he's older and I was able to explain to him what was going to happen. They had headphones on him so he was able to talk to the MRI people and he could see us at the end of the machine through a mirror that reflected so he wasn't to scared. His MRI's are of the head and his only take about 20-30 mins."
Web Links
Interesting sites on MRI.
- Everything you wanted to know, and more, is at a site by Joseph Hornak, at the Rochester Institute of Technology. He has essentially created a Hypertext on MRI. Tons of math for the interested.
- Your mri exam at Joseph Hornak's site. If you miss the rest of the site, at least go here for a discription of an exam.


text:
To Write Love on Her Arms is a nonprofit movement dedicated to presenting hope and finding help for people struggling with depression, addiction, self-injury, and suicide. TWLOHA exists to encourage, inform, inspire and also to invest directly into treatment and recovery. As James Earl Jones explains in six words in this video, "Help is real, hope is real."
Visit TWLOHA, join its Facebook page, and follow TWLOHA on Twitter.
Dyslexic student plays piano exquisitely. Awestruck.
©2005 - 2017 Six Words, LLC


text:
Made of ballistic nylon covered foam pads, these 36 in. Roof Rack Pads protect your canoe or kayak and roof rack from damage. Secure with velcro closures and bungee ties at each end.
|Item #:
|3 ft / 0.91 m
|Part Number
|Logo - 36 in - Reg
|Non-Logo - 36 in - Reg
Pads fit exactly the width of my Yakima Load Warrior for my Heritage kayak.
Had bought similarpads from another vendor previously. These were less money so I gave them a try. Only difference is these have thinner internal foam so I lost a little protection. Otherwise about the same fabric, Velco straps and bungee end ties.
Put on my Yakama cross bars for my SUP. Works just as described. Great quality at a great price. Others I found were much more expensive and why would you pay more? They are just what I was looking for. Bought 2 sets for both cars.
Good product overall. A few of the seams along the velcro staps could have been sewn a little better.


text:
Today I came across this great analysis by Neil Patel about differences in demographics on social media. Because vacation rental business is a very unique niche I thought it's very important to understand where your prospective clients spend most of their time.
A couple of years ago I read another study about who is doing all the prep work for an upcoming vacation. Although in our family all travel planning is done by me I wasn't surprised to learn that in most of the cases it's actually the opposite. Women take care of this task.
The infographic below gives you a clear picture of the best channels to market your vacation rental. Well, as long as you know who your clients are:


text:
|25th week of 2010 patent applcation highlights part 48
|Patent application number
|HEAT PIPE, HEAT PIPE REFORMER COMPRISING SUCH A HEAT PIPE, AND METHOD FOR THE OPERATION OF SUCH A HEAT PIPE REFORMER - A heat pipe and a method for operating a heat pipe of said type are provided, which heat pipe remains active over a relatively long period of time in particular when used in pressurized gasification atmosphere, that is to say in a hydrogen-rich environment. Also specified is a heat pipe reformer having a heat pipe of said type. By providing a hydrogen extractor in the region of the heat-dissipating end of the heat pipe, the hydrogen which has penetrated into the heat pipe and accumulated there is conducted out of the heat pipe again, such that the heat-exchanging capacity of the heat pipe is maintained. The hydrogen extractor generates a hydrogen concentration gradient or a hydrogen partial pressure gradient between the interior and the exterior of the pipe casing, such that hydrogen which has penetrated into the interior of the heat pipe is diffused into the hydrogen extractor and can be extracted from there. A hydrogen concentration gradient or hydrogen partial pressure gradient is also formed between the atmosphere surrounding the heat pipe, for example the atmosphere in a reforming fluidized-bed gasification chamber, and the hydrogen extractor, such that hydrogen from the surrounding atmosphere is also diffused into the hydrogen extractor and extracted from there.
|METHODS AND SYSTEMS FOR ASSESSING LUNG FUNCTION AND DELIVERING THERAPEUTIC AGENTS - Methods and systems for isolating, assessing and treating lung compartments are disclosed. One or more lung compartments are accessed through an isolation catheter, oxygen rich gas is delivered to the compartments, and blood oxygen or exhaled carbon dioxide are monitored to assess lung compartment function. Diseased lung compartments may be treated using therapeutic agents delivered to the diseased compartments through the isolation catheter. Therapeutic agents include carbon monoxide, radioactive agents, chemotherapeutic agents or angiogenesis inhibitors and angiocidal agents.
|AMIDES OF HYALURONIC ACID AND THE DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION - An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R═NR
|USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A
|FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity - The present invention embraces compounds selected for interacting with the Fingers-Palm pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase.
|METHOD AND COMPOSITION FOR BIOACTIVE AGENT RELEASE IN VIVO - A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate).
|DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION - The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.
|METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
|Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies - The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
|Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.
|METHOD FOR THE USE OF [11C] CARBON MONOXIDE IN LABELING SYNTHESIS OF 11C-LABELLED ESTERS AND ACIDS BY SENSITIZED PHOTO-INDUCED FREE RADICAL CARBONYLATION - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with alcohols or water treated by photosensitizers are provided. The resultant carbon-isotope labeled esters and acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided.
|QUANTUM DOT LABELED STEM CELLS FOR USE IN CARDIAC REPAIR - The present invention provides methods and compositions relating to the labeling of target cells with quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been administered to a subject to promote cardiac repair. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host.
|Compositions for Delivery of Therapeutics and Other Materials - This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.
|RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder.
|Altered Activity of Toll-Like Receptors - Materials and Methods for modulating TLR activity are described, as well as methods for reducing body fat and increasing bone density.
|TRUNCATED PAP2 AND METHODS OF MAKING AND USING SAME - A method of treating pancreatitis is provided, including the steps of: providing a mammal having pancreatitis; and administering a therapeutically effective amount of a truncated N-terminal PAP2; and making of an antibody specifically directed to detect PAP2.
|Enhanced 13C NMR By Thermal Mixing With Hyperpolarized 129XE - A method of preparing a hydrogen-containing
|ASSESSING BRAIN ANEURYSMS - This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided.
|Anti-Cancer Medicine Both for Diagnosing and Treating Cancer - Disclosed is an anti-cancer medicine comprising a chain end functionalized polymer, a contrast material such as iron oxide and a chemotherapeutic agent such as doxorubicin or pharmaceutically acceptable salts thereof. The anti-cancer medicine performs diagnosis and treatment of cancer at the same time, remarkably reduces a cardiotoxic side effect of the doxorubicin and has an excellent targeting function to the cancer part to considerably increase the anti-cancer effect. At the same time, the anti-cancer medicine is provided as MRI contrast medium which can diagnose the cancer and monitor a progress of the disease. In particular, the anti-cancer medicine is disclosed which is superior to the diagnosis and treatment of the solid cancer and can effectively perform the diagnosis and treatment of the metastatic cancer as well as the primary cancer at the same time.
|MICROBUBBLES AS DRUG DELIVERY DEVICE - A method of making PVA microbubbles including a functionalisation step in which PVA polymeric chains are functionalised at their ends with aldehyde groups, and a subsequent cross-linking step, in which in an air-aqueous solution emulsion with a pH between 4.5 and 5.5 the previously functionalised PVA polymeric chains cross-link by means of an acetalisation reaction, thereby forming the microbubbles. The microbubbles produced are subsequently subjected to a lyophilising step, a filling step in which medicinal gas is introduced and a restoration step of the microbubbles by adding an aqueous solution.
|Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof.
|Biological Cell Tracking With Ultrasound - This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.
|GAS BUBBLE-GENERATING AGENT - This invention provides a gas bubble-generating agent that can be used as a contrast medium or a blocking agent in vivo. Such gas bubble-generating agent is produced by a method for producing a gas bubble-generating agent comprising the following steps of: (a) preparing a mixed solution of an amphiphilic substance, an amphiphilic substance comprising a water-soluble polymer chemically bound thereto, a hardly water-soluble substance having a boiling point of lower than 60° C. at atmospheric pressure, and a physiologically acceptable isotonic solution; (b) pressurizing the mixed solution; and (c) centrifuging the mixed solution after the step of pressurization, wherein a molar concentration of the amphiphilic substance in the mixed solution prepared in step (a) is 10 times or more higher than that of the amphiphilic substance comprising a water-soluble polymer chemically bound thereto.
|T1 MRI TRACKABLE DRUG DELIVERY PARTICLES, USES AND METHODS THEREOF - The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising an internal and external distribution of magnetic resonance imaging contrast agents.
|ANTIMICROBIAL N-CHLORINATED COMPOSITIONS - The present application relates to N-chlorinated cationic compounds of Formula I
|Calcium Glycerophosphate for Treating and Preventing Respiratory Diseases or Conditions - Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway. The disease, disorder and/or condition can be a respiratory airway inflammatory disease, a respiratory airway stenosis or a nasal cavity inflammatory disease, such as an asthma, a chronic obstructive pulmonary disease (COPD), an emphysema, a reactive airway disease (RADS), rhinitis, bronchitis, bronchiolitis, congestion, sinusitis, tonsillitis, or laryngitis, post-nasal drip (PND) and a related complication thereof, inflamed degranulating and non-degranulating mast cell activity, any irritation occasioning mucus secretion from goblet cells breathing difficulty, restriction, obstruction; airways constriction or closure or mucus interference with air passage; sleep apnea, snoring, inflammatory or non-inflammatory responses to an airborne or non-airborne allergen or irritant; nasal or non-nasal airway inflammation or irritation caused by a problem in any area of the body; and a physical damage to the respiratory system. Methods, compositions and devices are described for using calcium glycerophosphate to treat and prevent the disease, disorder and/or condition of the respiratory system.
|XYLITOL DENTAL MAINTENANCE SYSTEM - A system, kit and method for promoting oral hygiene are disclosed. The kit may comprise several compositions or a single composition, each of which comprises an effective amount of xylitol. For example, the system and kit may comprise a chewing gum composition, a morsel composition, a paste-like composition, and an oral rinse composition; or any one of the above compositions; or any combination of the above compositions. It will be appreciated that a novel method for using such a system and kit for promoting oral hygiene may include: administering about 0.5 grams to about 2.0 grams of xylitol through the paste-like composition in the morning and in the evening, administering about 0.5 grams to about 2.0 grams of xylitol after consumption of nutrition through chewing the gum composition or through the morsel composition, and administering about 0.5 grams to about 1.5 grams of xylitol per application through the oral rinse composition.
|ANTIMICROBIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING THE SAME, AND METHODS OF USING THE COMPOSITIONS AND PRODUCTS - Antimicrobial agents, products and compositions incorporating the agents, and methods of using the compositions and products are provided. The antimicrobial agents comprise 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 2,2,4,4-tetramethyl-1,3-cyclobutanediol, or mixtures thereof. These agents have surprisingly been found to inhibit microbial growth at a much lower concentration than other glycols with known antimicrobial activity.
|PEPTIDES THAT BIND TO SILICA-COATED PARTICLES - Peptides having strong affinity for silica as well as surfaces comprising silica are described. The silica-binding peptides may be used to construct peptide based-reagents suitable for delivery of a silica-coated particulate benefit agent to a surface, such as body surface, for personal care and cosmetic applications. Peptide-based reagents formed by coupling at least one of the silica-binding peptides to at least one body surface-binding peptide, either directly or through a spacer, are described. The peptide-based reagents may be used in conjunction with at least one silica-coated colorant to color body surfaces.
|PEPTIDE LINKERS FOR EFFECTIVE MULTIVALENT PEPTIDE BINDING - Short single chain peptides having affinity for a target surface often lack the binding durability required for certain commercial applications. One way to improve durability is to promote multivalent binding by linking together binding sequences using peptide linkers. However, the resulting single chain binding peptides often suffer from linker entropy. It has been discovered that the use of rigid peptide linkers when linking together multiple binding sequences enhances the binding affinity of the resulting single chain peptide.
|SILICONE POLYETHER ELASTOMER GELS - Gel compositions are disclosed containing a silicone polyether elastomer from the reaction of an organohydrogensiloxane having at least two SiH containing cyclosiloxane rings in its molecule, a compound or mixture of compounds having at least two aliphatic unsaturated groups in its molecule, and a hydrosilylation catalyst. The silicone polyether elastomer reaction product may itself be a gelled composition, or optionally may be contained in a carrier fluid to form a gel. The gel compositions may further contain a personal or healthcare active.
|COSMETIC AND PERSONAL CARE PRODUCTS CONTAINING SYNTHETIC MAGNESIUM ALUMINO-SILICATE CLAYS - The invention provides for cosmetic and personal care compositions comprising a synthetic magnesium aluminosilicate clay. The synthetic magnesium aluminosilicate clay is formed at ambient pressure by a series of reaction steps and a pH change from acidic pH to basic pH. The characteristics of the magnesium aluminosilicate clay, including platelet size, degree of stacking, and porosity can be tuned depending on the cosmetic or personal care product desired. In addition, these cosmetic and personal care compositions optionally include one or more of the following components: odor controlling agents, skin protectants, diluents, lipophilic skin health benefit agents, sunscreens, humectants, emollients, slip compounds, and moisturizers.
|COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND SUGAR AMINES - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent and a sugar amine. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin.
|COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND PLANT EXTRACTS - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent, and a plant extract selected from the group consisting of extract of pre-germinated soy seeds, walnut seed extract, mugwort extract, and combinations thereof. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin.
|Topical Compositions Containing CIS-6-Nonenol and its Derivatives and Methods for Treating Skin - Cosmetic compositions comprising cis-6-nonenol and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. Cis-6-nonenol is believed to have modulatory activity against at least one biochemical pathway implicated in skin aging.
|Method and Composition for Color Modulation - The invention is directed to a method and composition suitable for skin color modulation. Particularly, the action of D-dopachrome tautomerase on melanogenesis and/or the transfer of melanin from melanosomes in keratinocytes is reduced, thereby resulting in a change in skin color.
|Multiphase Personal Care Composition With Enhanced Deposition - A multiphase personal care composition that comprises a structured surfactant phase and an oil continuous benefit phase. The structured surfactant phase comprises from about 5% to about 30% of a mixture of lathering surfactants, a lamellar inducing agent and a cationic polymer. The oil continuous benefit phase comprises a hydrocarbon based benefit material and a low HLB emulsifier. The low HLB emulsifier comprises an unsaturated monoglyceryl ester having from about 14 to about 30 carbon atoms. The oil continuous benefit phase comprises a ratio of said hydrocarbon based benefit materials to said low HLB emulsifier comprising from about 30:1 to about 200:1.
|Viscosity Regulator, Method For The Production Thereof, And Use Thereof - The present invention relates to a method for the production of a viscosity regulator by introducing hydrophobic and hydrophilic groups into a starch molecule. The invention also relates to viscosity regulators produced in this manner and the use thereof. The viscosity regulators according to the invention can be used as emulsifiers or as thickening agents of surfactant-containing systems, e.g. in cosmetic or pharmaceutical preparations.
|COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR POLYMER AND METHOD FOR MAKING UP THE SKIN AND/OR LIPS EMPLOYING A COMPOSITION COMPRISNG A SUPRAMOLECULAR POLYMER - The present disclosure relates to a method for making up the skin and/or lips, wherein a cosmetic makeup composition comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer is applied. The disclosure also relates to a cosmetic composition for making up the skin and/or lips, comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer and at least one coloring material.
|COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND PLANT EXTRACTS - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent, and a plant extract selected from the group consisting of extract of pre-germinated soy seeds, walnut seed extract, mugwort extract, and combinations thereof. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin.
|COMPOSITION COMPRISING AT LEAST TWO DIFFERENT CYCLOALKYLMETHICONES AND USE THEREOF - A cosmetic composition includes comprising a blend of cycloalkylmethicones comprising at least two different cycloalkylmethicones having general formula I:
|PLASTICIZER OF NATURAL ORIGIN FOR NAIL POLISH - The use of at least one carbonate of natural origin as a plasticizer in a film-forming cosmetic composition comprising, in a physiologically acceptable medium, a film-forming polymer and a solvent medium.
|Method of Coloring Nails and a Nail Polish Formulation - Various embodiments of this invention discloses a translucent and colored nail polish glaze, a nail polish base, and a method for combining nail polish base colors with translucent and colored nail polish glazes to create a multiple of different colors and color shades from a minimal number of nail polish base and glaze colors.
|IRON OXIDE-BINDING PEPTIDES - Peptides having strong affinity for iron oxide pigment particles have been identified. Peptide-based reagents comprising at least one of the present iron oxide-based pigment-binding peptides and at least one body surface-binding peptide are described. The peptide-based reagents may be used in conjunction with at least one iron oxide-based pigment to color body surfaces.
|NAIL VARNISH COMPRISING A SICCATIVE OIL AND A METAL SALT - The present invention relates to a nail varnish, characterized in that it comprises at least one siccative oil and at least one metal salt, and in that it comprises less than 5% by weight of volatile organic solvent(s) relative to the total weight of the nail varnish.
|OXIDIZING COMPOSITION FOR THE TREATMENT OF KERATIN FIBERS COMPRISING AT LEAST ONE CATIONIC POLYMER, AT LEAST ONE FATTY AMIDE AND AT LEAST ONE ANTI-OXYGEN AGENT - Provided is a composition for the treatment of keratin fibers, for example human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition ranges from 1.5 to 4.5. Also provided is a composition for the treatment of keratin fibers, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition is alkaline. Also provided is a method for treating keratin fibers, comprising applying, to the keratin fibers, at least one oxidizing composition described herein.
|DEODORANT COMPOSITION - The present invention relates to a deodorant composition containing (a) a polyphenol compound or a plant extract containing a polyphenol compound, (b) a basic substance, and (c) a metal salt. The deodorant composition of the present invention is capable of providing a deodorizing effect in a short period of time when it is applied to a malodor source, is capable of providing an excellent deodorizing activity and is also excellent in the store stability.
|DEODORANT COMPOSITIONS - A gelled composition is provided which comprises:
|NATURAL SKIN WHITENER: 4-HYDROXY-OXINDOLE-3-ACETIC ACID - A cosmetic and dermatological composition comprises 2, 3-dihydro-4-hydroxy-2-oxo-1-H-indole-3-acetic acid (4-hydroxy-1-oxindole-3-acetic acid) as an active ingredient for use as a melanin inhibitor and as an anti-tyrosinase enzyme inhibitor. This composition is excellent as a skin whitening agent. Since it also has potent antioxidant and anti-irritant activities it is useful in a cosmetic composition for improving hyperpigmentation disorders of the skin.
|NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenylpropanoic acid compounds have the general formula (I) below:
|OXIDIZING COMPOSITION FOR THE TREATMENT OF KERATIN FIBERS COMPRISING AT LEAST ONE OIL, ATLEAST ONE FATTY ALCOHOL AND AT LEAST ONE OXYALKYLENATED FATTY ALCOHOL - Provided herein is a composition for the treatment of keratin fibers comprising, a cosmetically acceptable medium; at least one fatty alcohol; at least one oxyalkylenated fatty alcohol; at least one oxidizing agent; and at least one oil other than a fatty alcohol present in an amount greater than or equal to 10% by weight relative to the total weight of the composition, wherein the weight ratio of the at least one fatty alcohol to the at least one oxyalkylenated fatty alcohol has a value less than or equal to 5; and further wherein the pH of the composition ranges from 1.5 to 4.5. Also provided herein is a composition for the treatment of keratin fibers comprising, a cosmetically acceptable medium; at least one fatty alcohol present in an amount ranging from 3 to 25% by weight relative to the total weight of the composition; at least one oxyalkylenated fatty alcohol; at least one oxidizing agent; and at least one oil other than a fatty alcohol present in an amount greater than or equal to 10% by weight relative to the total weight of the composition, wherein the weight ratio of the at least one fatty alcohol to the at least one oxyalkylenated fatty alcohol has a value less than or equal to 5; and further wherein the pH of the composition is alkaline. Also provided herein is a method for treating keratin fibers, comprising applying to the keratin fibers at least one oxidizing composition described herein.
|COMPOSITION AND PROCESS FOR RELAXING OR STRAIGHTENING HAIR - The present invention is directed to composition for straightening or relaxing hair containing: (a) at least one hydroxide-containing active ingredient; (b) at least one polyhydric alcohol having 4 or more carbon atoms and two hydroxyl groups; (c) optionally, at least one nonionic surfactant having an HLB of from about 8 to about 20; (d) optionally, at least one amphoteric and/or zwitterionic surfactant; and (e) remainder, to 100%, of a cosmetically suitable medium.
|HAIR-BINDING PEPTIDES - Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.
|HAIR-BINDING PEPTIDES - Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided.
|COSMETIC COMPOSITION COMPRISING A BRANCHED SULPHONIC POLYESTER AND A SURFACTANT AND USES IN HAIR STYLING - The present application relates to a cosmetic composition comprising, in a cosmetically acceptable medium: at least one branched sulphonic polyester, and at least one non-ionic oxyalkylenated or glycerolated surfactant. The present application also relates to the uses of this composition, for example for the styling and the shaping of the hair.
|ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT - A novel macromer or mixture thereof is described herein, comprising isocyanatophenyl ether terminal moieties and at least two residues of a water-soluble polymer having a molecular weight ranging from 80 to 10,000 adjacent to the ether group of the isocyanatophenyl ether terminal isocyanate moieties, thereby forming at least two ether linkages in the macromer or mixture thereof. A method for making a polyisocyanate macromer is also described herein.
|DENDRIMER BASED MODULAR PLATFORMS - The present invention relates to novel therapeutic and diagnostic dendrimer based modular platforms (e.g., drug delivery platforms). In particular, the dendrimer based modular platforms are configured such that two or more dendrimers (e.g., PAMAM dendrimers) are coupled together (e.g., via a cycloaddition reaction) wherein each of the coupled dendrimers is functionalized (e.g., functionalized for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy). In some embodiments, the present invention provides dendrimer based modular platforms having coupled dendrimers (e.g., two or more coupled dendrimers) wherein each dendrimer is conjugated to one or more functional groups (e.g., therapeutic agent, imaging agent, targeting agent, triggering agent) (e.g., for specific targeting and/or therapeutic use of the dendrimer based modular platform). In some embodiments, the functional groups are conjugated to the dendrimers via a linker and/or a triggering agent. In addition, the present invention is directed to methods of synthesizing dendrimer based modular platforms, compositions comprising the dendrimer based modular platforms, as well as systems and methods utilizing the dendrimer based modular platforms (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)).
|MATERIAL FOR FORMING A MULTI-LEVEL ANTIMICROBIAL SURFACE COATING AND ITS PREPARATION - The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material.
|METHOD FOR REDUCTION OF MICROBES ON SURFACES - A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a polyalkyleneoxide polysiloxane surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations.
|POLYALKYLENE OXIDE POLYQUATERNARY AMMONIUM BIOCIDES - Disclosed are polyquaternary ammonium polymers containing polyalkylene oxide groups according to formula (I) wherein [A]
|METHOD FOR TREATMENT OF AIRWAY AND APPARATUS AND KIT FOR USE THEREWITH - A method of treating an airway in a mammalian body having a mouth, soft palate, uvula, throat and tongue. An implant-forming material is introduced into at least one of the soft palate and uvula for treating at least one of snoring and sleep apnea. An apparatus and kit are provided.
|METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety.
|Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided.
|Compositions and methods for the inhibition of endothelial nitric oxide synthase activity - The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods.
|ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES - In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject.
|ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.
|HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein A, R
|TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH COMPOSITIONS COMPRISING EXTRACTS OF ASTRAGALUS MEMBRANACEUS - The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of
|Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
|TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS - A quinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof: formula (I) for use in treatment of prevention of a flaviviridae infection.
|ANTIVIRAL PRODUCT - The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb
|Inhibitor of endogenous human interferon-gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ, inactivated by physical or chemical methods.
|PREDICTION OF HCV TREATMENT RESPONSE - The present invention is based on the discovery that in patients infected with Hepatitis C Virus Genotype 1 (HCV-1) or Genotype 4 (HCV-4), a beneficial response to a treatment that includes interferon alpha, ribavirin and a HCV polymerase inhibitor could be predicted if the patient's HCV RNA level becomes undetectable in as short as two weeks post treatment.
|PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF - The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
|Use of Fetal Cells for the Treatment of Genetic Diseases - The present invention provides iPS and stem cells derived from fetal somatic cells derived from a fetus in utero or from cord blood. The iPS and stem cells can be stored or used to treat genetic diseases.
|COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OF HUNTINGTON'S DISEASE THROUGH INTRACRANIAL DELIVERY OF SIRNA - The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient.
|NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against
|Sickled erythrocytes with antitumor molecules induce tumoricidal effects - The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect.
|Cardiomyocyte Cell Populations - The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy.
|METHOD FOR EXTRACTING AND SELECTING CELLS - Method for selecting cells, comprising at least one at least partially combined step of enzymatic digestion and of selection in culture.
|Compositions and Methods for Treating Peripheral Vascular Diseases - The invention relates to methods for producing endothelial cells, pericytes and/or muscle cells (in particular smooth muscle cells), cell preparations and pharmaceutical compositions comprising the cells or preparations, and the use of the cells, preparations and compositions in research or commercial applications. In aspects, the invention provides a method of treating a patient with a condition involving endothelial cells, endothelial precursor cells, pericytes and/or muscle cells, such as a peripheral vascular disease, comprising administering to the patient endothelial precursor cells, endothelial cells, pericytes and/or muscle cells obtained from multipotent CD45
|MUSCLE DERIVED CELLS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux.
|PROCESS FOR THE PREPARATION OF STEM CELLS FROM HUMAN MUSCLE TISSUE AND ADIPOSE TISSUE, AND STEM CELLS OBTAINABLE BY THIS PROCESS - The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process.
|TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS - Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient.
|TARGET POPULATIONS OF OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF MAKING AND USING SAME - This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons.
|EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES - The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided.
|REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY - Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed.
|ACTIVATED DUAL SPECIFICITY LYMPHOCYTES AND THEIR METHODS OF USE - The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.
|IMMUNOMODULATING PROBIOTIC LACTIC ACID BACTERIA - The present invention relates to immuno modulating probiotic lactic acid bacteria, to methods wherein the bacteria are used to reduce allergy, and to food products wherein the bacteria may be in incorporated to reduce allergy upon consumption of the product. Preferred probiotic lactic acid bacteria stimulate the Th1 and/or Th3 responses and/or represses Th2 responses as may be determined by the cytokine profiles that are induced in human peripheral blood mononuclear cells upon coincubation with the lactic acid bacteria.
|Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis - A method of suppressing angiogenesis in a mammal (e.g., for treating tumors, tumor metastasis or a condition that would benefit from decreased angiogenesis) comprises the step of administering to the mammal an angiostatically effective amount of a pharmaceutical composition comprising an isolated antiangiogenic truncated tryptophanyl-tRNA synthetase (TrpRS) polypeptide or an isolated nucleic acid that comprises a polynucleotide sequence that encodes the truncated TrpRS polypeptide. The truncated TrpRS polypeptide comprises residues 71-471 of SEQ ID NO: 10, residues 48-471 of SEQ ID NO: 10, or a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO: 10 with polymorphonuclear leucocyte elastase.
|Cascade - The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.
|METHOD AND MATERIAL FOR SITE ACTIVATED COMPLEXING OF BIOLOGIC MOLECULES - Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities.
|Triple acting antimicrobials that are refractory to resistance development - Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live
|DIRECT APPLICATION OF NON-TOXIC CROSSLINKING REAGENTS TO RESIST PROGRESSIVE SPINAL DEGENERATION AND DEFORMITY - A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue.
|USE OF ALKALINE PHOSPHATASE TO MAINTAIN HEALTHY TISSUE MASS IN MAMMALS - Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy.
|ENHANCING THE EFFECT OF THERAPEUTIC PROTEINS ON THE CENTRAL NERVOUS SYSTEM - The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human β-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient.
|USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay.
|Human Coagulation Factor VII Variants - The present invention encompasses isolated human coagulation Factor VII variants comprising a substitution of Phe in position 374 of SEQ ID NO 1 with another amino acid residue.
|PEST CONTROL - The present invention relates to novel rodent control agents comprising antibodies, or antigen-binding fragments thereof, that bind to proteins expressed in rodents and in particular antibodies or antigen-binding fragments that bind to proteins expressed in the gastrointestinal (GI) tract of rodents, as well as to methods of making such novel rodent control agents. The invention further extends to novel antibodies and antigen-binding fragments for use in rodent control as well as to methods of controlling rodents through the use of such antibodies, antigen binding fragments and novel rodent control agents.
|SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.